U.S. markets open in 4 hours 3 minutes

Processa Pharmaceuticals, Inc. (PCSA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.17+0.81 (+12.74%)
At close: 4:00PM EST

Processa Pharmaceuticals, Inc.

7380 Coca Cola Drive
Suite 106
Hanover, MD 21076
United States
443 776 3133
http://www.processapharmaceuticals.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Dr. David YoungCo-Founder, Chairman, Pres & CEON/AN/A1953
Mr. Patrick LinCo-Founder, Chief Bus. & Strategy Officer52.5kN/A1965
Dr. Sian E. Bigora Ph.D., Pharm.D.Co-Founder & Chief Devel. Officer52.5kN/A1960
Ms. Wendy J. GuyCo-Founder & Chief Admin. Officer87.5kN/A1964
Mr. James H. StankerChief Financial Officer87.5kN/A1958
Mr. Robert Michael FloydChief Operating OfficerN/AN/A1956
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops drugs for the unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of post-operative ileus; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It also has license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was founded in 2015 and is based in Hanover, Maryland.

Corporate Governance

Processa Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.